Tarrytown, N.Y., August 30, 2009 – PsychoGenics Inc. and AstraZeneca have entered into a drug discovery and development agreement to identify compounds that are likely to be useful for the treatment of certain Central Nervous System (CNS) disorders. Under the agreement, PsychoGenics will use its proprietary drug discovery technologies to evaluate a number of AstraZeneca drug candidates for their potential to treat psychiatric disorders. Read More.
TARRYTOWN, N.Y., August 10, 2009 – PsychoGenics Inc., announced the appointment of David A. Lowe, Ph.D., as Chief Scientific Officer (CSO) and Executive Vice President of Research and Development (EVP, R&D). Read More.
TARRYTOWN, N.Y., August 25, 2008 – PsychoGenics Inc., announces the appointment of John McCall, Ph.D., as a member of its Scientific Advisory Board, reflecting the company’s growth in the areas of Drug Discovery and Development. Read More.
Tarrytown, N.Y., June 02, 2008 – PsychoGenics Inc. today announced positive data from its randomized, placebo controlled, multicenter, Phase IIa trial of eltoprazine, the company’s lead partial 5-HT1A – 5-HT1B receptor agonist, in adult patients with Attention Deficit/ Hyperactivity Disorder (ADHD). The primary objective of the exploratory study was to compare the effects of two doses of eltoprazine with placebo in a cross-over design on the symptoms of ADHD in adults using the total scores from the ADHD Rating Scale-Version IV. Read More.
TARRYTOWN, N.Y., May 28, 2008 – PsychoGenics Inc., announced the appointment of Bavani Shankar, as Vice President of Corporate Development. This appointment reflects the company’s growth and expansion into new areas of CNS drug discovery and development. Read More.
Tarrytown, N.Y., May 27, 2008 – PsychoGenics Inc., and Roche, Basel, Switzerland, have entered into a drug discovery and development agreement in which they combine their complementary strengths and expertise to identify a new generation of treatments for neuropsychiatric disorders. Read More.
Tarrytown, NY, Mar 4, 2008 – PsychoGenics Inc. and Dainippon Sumitomo Pharma, Co., Ltd., Japan, have entered into a drug discovery agreement to screen selected Dainippon Sumitomo Pharma compounds in PsychoGenics’ proprietary Drug Discovery Systems, with the aim of identifying new therapies for CNS disorders. Read More.
Tarrytown, NY, Jan 31, 2008 – PsychoGenics Inc. today announced that it has entered into an additional drug discovery agreement with Eli Lilly and Company (NYSE:LLY). Per the agreement, Lilly will supply pre-candidate compounds that PsychoGenics will evaluate using its proprietary drug discovery technologies, for the treatment of neuropsychiatric disorders. Read More.
Tarrytown, NY, November 7, 2007 – PsychoGenics Inc. today announced that it has entered into a drug discovery agreement with Cephalon, Inc. The agreement provides that Cephalon will supply compounds that are prospectively suitable for neuropsychiatric disorders to PsychoGenics for evaluation using its proprietary drug discovery technologies. Read More.
Washington, D.C. ,April 13, 2007 -- Translational research and the individuals who help to support it will be a major highlight of the Sunday programming at the 2007 Biotechnology Industry Organization (BIO) International Convention. Read More.
Tarrytown, NY, January 30, 2007 – PsychoGenics Inc. announced today that together with Amylin Pharmaceuticals, Inc. they have formed Psylin Neurosciences, Inc. (Psylin), a new company that will focus on the discovery and development of peptide hormones for treatment of psychiatric disorders. PsychoGenics and Amylin participated equally in a Series A financing of Psylin anticipated to fund the company for approximately the next two years. Read More.
The BIO 2007 Translational Research Forum seeks to bring together the major funders of translational research in a full-day program. The speakers and panelists will explore their criteria for selecting and funding programs, as well as describe how pharmaceutical and biotechnology companies and academic centers can be involved in foundation and NIH-driven translational research. Read More.
Dec 19, 2006 – PsychoGenics Inc. today announced that it has entered into a drug discovery and development agreement with Eli Lilly and Company (NYSE: LLY). Per the agreement, Lilly will provide drug candidates that PsychoGenics will evaluate, using its proprietary drug discovery technologies, for the treatment of neuropsychiatric disorders. Read More.
October 4, 2006 – PsychoGenics Inc. announced the appointment of Rusiko Bourtchouladze, Ph.D., as Vice President, Cognition and Discovery Research. This appointment reflects the company’s expansion and commitment to cognition and drug discovery. Read More.
September 22, 2006 &hdash; PsychoGenics Inc. Tarrytown, New York has expanded its research collaboration with the High Q Foundation and CHDI Inc. to phenotype transgenic mouse models of Huntington Disease (HD) and evaluate potential therapeutics in those models. Read More.
April 10, 2006 – PsychoGenics Inc., Tarrytown, NY and Sosei Co. Ltd., Japan, have entered into a drug discovery collaboration combining Sosei’s Drug Reprofiling Platform and PsychoGenics’ proprietary Drug Discovery Systems. This collaboration aims to rapidly discover and bring to market new CNS therapies. Read More.
February 24, 2006 – PsychoGenics Inc. Tarrytown, New York and the Spinal Muscular Atrophy (SMA) Foundation have extended their research agreement to establish and behaviorally phenotype transgenic in vivo models of SMA and test potential therapeutics using these models. As part of this collaborative agreement PsychoGenics has established self-sustaining transgenic SMA colonies and characterized the progression of behavioral and motor deficits in these mice over time. A rapid throughput battery of discriminatory tests has been developed to evaluate candidate drugs and therapies in these models to treat spinal muscular atrophy. Read More.
July 6, 2005 – PsychoGenics Inc. Tarrytown, New York has signed a license agreement enabling it to provide behavioral phenotyping and compound evaluation services using the transgenic R6/2 mouse model for Huntington Disease. Huntington Disease is a devastating and ultimately fatal neurological condition for which no treatment currently exists. The Huntington animal model provides a valuable discovery tool to aid in the development of much needed drugs.Under the terms of the license agreement, PsychoGenics is now able to provide third-party testing in the R6/2 model. The terms of the agreement are undisclosed, however, there are no reach-through obligations on PsychoGenics’ clients. Read More.
November 15, 2004 – PsychoGenics, Inc., a leader in preclinical neurobiology and CNS drug discovery solutions, today announced an expansion of its executive management team. Effective immediately Paul McGonigle, Ph.D., co-founder and former CEO of NeuroGenix Corporation, has been named Chief Scientific Officer, and Jeff Schneider, Ph.D., Associate Research Professor at Carnegie Mellon University’s Robotics Institute, has been appointed Chief Informatics Officer. Read More.
Hawthorne, New York, August 28, 2002, PsychoGenics Inc. announced today that its application to the National Institute of Mental Health of the National Institutes of Health for a fast-track (Phase I and II) Small Business Innovation Research (SBIR) grant, totaling $1,062,158, has been approved. The grant will help support the further development of SmartCubeTM, the first proprietary high-throughput system for testing behavior and physiology in live animals (in vivo). SmartCubeTM combines the company’s expertise in behavioral pharmacology with innovations in robotics, computer vision and bioinformatics, bringing massively parallel data acquisition and analysis to the study of behavior and a new approach to central nervous system (CNS) drug discovery. Read More.
Hawthorne, New York, June 11, 2002, PsychoGenics Inc, a private biopharmaceutical company, with expertise in the field of behavioral neurobiology, and provider CNS drug discovery solutions to Pharmaceutical and Biotechnology companies, announces that Mark Hofer, Esq. has joined the Company as General Counsel taking a partial leave of absence to do so from Brown Rudnick Berlack & Israels, a general practice law firm headquartered in Boston with offices in New England, New York and London, where he headed the Firms biotech intellectual property group. Read More.